Non conclusive data would most likely relate to the MRI data, which is not being released. It's not likely that biomarker data would be inconclusive since PAR are measuring several biomarkers and will probably only report those that are showing positive changes, so I have high confidence PAR will meet the primary endpoint which only requires significant change to a single biomarker out of 10 or more.
My biggest concern is the pain and function results (a secondary endpoint) due to the size of the trial, changes to trial protocol, drop outs, covid impacts etc. If, however, efficacy is found to be the same or better than 005 and the EAP, then this would be a very positive sign and would significantly derisk and rerate PAR. While the market may not see it that way at first, the market will catch up eventually.
My views only, not advice
- Forums
- ASX - By Stock
- PAR
- Ann: Successful Completion of Entitlement Offer
Ann: Successful Completion of Entitlement Offer, page-91
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAR (ASX) to my watchlist
|
|||||
Last
24.5¢ |
Change
-0.015(5.77%) |
Mkt cap ! $85.70M |
Open | High | Low | Value | Volume |
26.0¢ | 26.0¢ | 24.5¢ | $265.4K | 1.050M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 130186 | 24.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
25.0¢ | 11571 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
8 | 130186 | 0.245 |
8 | 120363 | 0.240 |
5 | 126753 | 0.235 |
5 | 146782 | 0.230 |
2 | 53000 | 0.225 |
Price($) | Vol. | No. |
---|---|---|
0.250 | 11571 | 1 |
0.260 | 15236 | 1 |
0.265 | 59987 | 2 |
0.270 | 10000 | 1 |
0.275 | 16347 | 3 |
Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, CEO
Anthony Noble
CEO
SPONSORED BY The Market Online